GALDERMA
11.2.2014 10:51:50 CET | Business Wire | Pressemeddelelse
Today, Nestlé S.A. (Nestlé) announced the creation of Nestlé Skin Health S.A., a global leader focused on meeting the world’s increasing skin health needs with a scientifically-proven broad range of innovative products. The company will be formed by the acquisition of 50% of Galderma Pharma S.A. (Galderma), subject to regulatory clearance. Galderma was established in 1981 as a dermatology-focused, Swiss-based joint-venture between Nestlé and L’Oréal S.A. (L’Oréal) and had sales of CHF € 2.0 billion in calendar year 2013.
Nestlé chairman Peter Brabeck-Letmathe said “Building on Nestlé’s
historic strengths as a science based Nutrition, Health & Wellness
Company and through the recent creation of Nestlé Health Science S.A.,
the company has reinforced its strategic direction to offer nutritional
solutions from food & beverage to scientific products for a healthier
life. By creating Nestlé Skin Health S.A. and by leveraging Galderma’s
current portfolio, formulations and innovative research, Nestlé will now
be able to provide science-based solutions for skin conditions. We
strive to have a portfolio of innovative products that meet the full
spectrum of people’s skin health needs over the course of their lives
and to provide a holistic approach to people’s health.”
The
establishment of Nestlé Skin Health will allow the emergence of a global
leader that will leverage Galderma’s and Nestlé’s commercial operations
throughout the world. Galderma’s Scientific Division, with laboratories
located in France, Sweden, United States, Japan and Switzerland, will
become part of Nestlé Skin Health and will actively collaborate with
Nestlé’s global R&D network. Galderma’s 33 commercial subsidiaries
around the world will continue to deliver scientifically-defined and
medically-proven products to patients and healthcare providers around
the world under the Galderma brand and organization.
Nestlé CEO Paul Bulcke said that “Nestlé Skin Health will have a broad commercial and R&D platform able to deliver state of the art solutions focused on maintaining, treating and restoring the health of the skin. The new company will be particularly effective working across different trade channels to help people meet their skin health needs at a time when access to medical care is getting more challenging due to resource constraints.” He added “Nestlé will contribute its Bübchen line of baby care products to Nestlé Skin Health and provide Galderma access to innovative technologies from Nestlé’s R&D as well to help develop Nestlé Skin Health’s future portfolio.”
Nestlé Skin Health will have a full range of products for the skin, hair and nail including self-medication drugs, quasi-drugs such as medicated soaps or sunscreens, therapeutic skin care products, nutraceuticals, prescription drugs and medical devices. Nestlé Skin Health, a wholly-owned subsidiary of Nestlé, will become operational as soon as regulatory requirements and competition authority clearance have been provided. Humberto C. Antunes, who currently serves as President and CEO of Galderma, will lead Nestlé Skin Health reporting to the company’s new Board of Directors. Peter Brabeck-Letmathe will become Chairman and Paul Bulcke Vice-chairman of the new Board of Directors of Nestlé Skin Health, based in Switzerland.
On behalf of Galderma, Humberto C. Antunes, CEO explained “this is good news for patients, consumers and healthcare providers, and the thousands of Galderma employees throughout the world. As part of Nestlé Skin Health, Galderma’s medical heritage and portfolio can be expanded to meet the full range of skin health needs, creating a new world leader focused on improving people’s lives.”
The skin, the largest organ in the human body, plays an important role in how we perceive ourselves and how others perceive us. Improving skin health has a proven impact on well-being and quality of life and these aspects, together with preventing, treating and curing medical conditions related to the skin, are what Nestlé Skin Health aspires to address.
About Nestlé Skin Health
Responding to increasing consumer needs, Nestlé will extend its activities to include the field of specialized, medical skin treatments through the creation of Nestlé Skin Health S.A., a global leader focused on meeting the world’s increasing skin health needs with a scientifically-proven broad range of innovative products. Nestlé Skin Health S.A. will be managed as a wholly-owned subsidiary of Nestlé S.A., with its own Board of Directors, located in Lausanne, Switzerland. Upon the approval and completion of Nestlé’s acquisition of the 50% stake of Galderma from L’Oréal, Galderma will form the foundation of Nestlé Skin Health S.A.
About Galderma
A global company exclusively dedicated to dermatology
Galderma
is a global company founded in 1981 committed to delivering innovative
medical solutions to meet the dermatological needs of people throughout
their lifetime while serving healthcare professionals around the world.
The company has 33 wholly-owned affiliates with a worldwide network of
distributors and more than 5,000 employees. Galderma’s extensive product
portfolio is available in 80 countries and treats a range of
dermatological conditions including: acne, rosacea, onychomycosis,
psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin
cancer and medical solutions for skin senescence.
With approximately 19% of revenues invested each year to discover and develop new products and access innovative technologies, the company is one of the world’s leading investors in dermatology R&D. Five state-of-the-art R&D centers and five manufacturing sites are dedicated to providing a wide range of innovative medical solutions which meet the highest standards of safety and efficacy.
Strategic brands include Epiduo, Oracea, Clobex, Differin, Mirvaso, Rozex/MetroGel, Silkis/Vectical, Tri-Luma, Loceryl, Cetaphil, Metvix, Azzalure, Restylane and Emervel.
For more information, please visit Galderma’s website www.galderma.com .
<>
Contact:
Galderma
Media Contact:
Karin Falck, Phone: +41 79 722
6075
Public & Media Relations Officer
For any question,
please contact communication@galderma.com
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
